104
Views
16
CrossRef citations to date
0
Altmetric
Review

Approaches to hepatitis C treatment and cure using NS5A inhibitors

, , , , , , & show all
Pages 41-56 | Published online: 05 Mar 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Christine Hong Ting Yang, Aparna Goel & Aijaz Ahmed. (2018) Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C. Adolescent Health, Medicine and Therapeutics 9, pages 103-110.
Read now
Aravindhan Ganesan & Khaled Barakat. (2017) Applications of computer-aided approaches in the development of hepatitis C antiviral agents. Expert Opinion on Drug Discovery 12:4, pages 407-425.
Read now
Yan A. Ivanenkov, Vladimir A. Aladinskiy, Nikolay A. Bushkov, Andrey A. Ayginin, Alexander G. Majouga & Alexandre V. Ivachtchenko. (2017) Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015). Expert Opinion on Therapeutic Patents 27:4, pages 401-414.
Read now
Muhammad Usman Mirza, Noor-Ul-Huda Ghori, Nazia Ikram, Abdur Rehman Adil & Sadia Manzoor. (2015) Pharmacoinformatics approach for investigation of alternative potential hepatitis C virus nonstructural protein 5B inhibitors. Drug Design, Development and Therapy 9, pages 1825-1841.
Read now
Annarosa Floreani. (2015) Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C. Expert Opinion on Pharmacotherapy 16:6, pages 801-804.
Read now

Articles from other publishers (11)

Ana Matošević & Anita Bosak. (2020) Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents. Archives of Industrial Hygiene and Toxicology 71:4, pages 285-299.
Crossref
Karen K. Kyuregyan, Vera S. Kichatova, Anastasiya A. Karlsen, Olga V. Isaeva, Sergei A. Solonin, Stefan Petkov, Morten Nielsen, Maria G. Isaguliants & Mikhail I. Mikhailov. (2020) Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C. Biomedicines 8:4, pages 80.
Crossref
Alaa R. S. Leila, Mai H. A. Mousa, Efseveia Frakolaki, Niki Vassilaki, Ralf Bartenschlager, Grigoris Zoidis, Mohammad Abdel-Halim & Ashraf H. Abadi. (2019) Symmetric Anti-HCV Agents: Synthesis, Antiviral Properties, and Conformational Aspects of Core Scaffolds. ACS Omega 4:7, pages 11440-11454.
Crossref
Keivan Zandi, Leda Bassit, Franck Amblard, Bryan D. Cox, Pouya Hassandarvish, Ehsan Moghaddam, Andrew Yueh, Gisele Olinto Libanio Rodrigues, Ingredy Passos, Vivian V. Costa, Sazaly AbuBakar, Longhu Zhou, James Kohler, Mauro M. Teixeira & Raymond F. Schinazi. (2019) Nucleoside Analogs with Selective Antiviral Activity against Dengue Fever and Japanese Encephalitis Viruses. Antimicrobial Agents and Chemotherapy 63:7.
Crossref
Serap Beldar, Malathy Sony Subramanian Manimekalai, Nam-Joon Cho, Kwanghee Baek, Gerhard Grüber & Ho Sup Yoon. (2018) Self-association and conformational variation of NS5A domain 1 of hepatitis C virus. Journal of General Virology 99:2, pages 194-208.
Crossref
Steven W. Johnson, Dorothea K. Thompson & Brianne Raccor. (2017) Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions. Current Infectious Disease Reports 19:6.
Crossref
Marawan Ahmed, Abhishek Pal, Michael Houghton & Khaled Barakat. (2016) A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry. ACS Infectious Diseases 2:11, pages 872-881.
Crossref
Shanshan Wang, Yongzhi Chen, Chunfeng Li, Yaoxing Wu, Lei Guo, Changwei Peng, Yueping Huang, Genhong Cheng & F. Xiao-Feng Qin. (2016) TRIM14 inhibits hepatitis C virus infection by SPRY domain-dependent targeted degradation of the viral NS5A protein. Scientific Reports 6:1.
Crossref
Javier Ampuero. (2016) Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. World Journal of Gastroenterology 22:22, pages 5285.
Crossref
Akihiro Tamori, Masaru Enomoto & Norifumi Kawada. (2016) Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators of Inflammation 2016, pages 1-11.
Crossref
Daniele Serranti, Giuseppe Indolfi & Massimo Resti. (2014) New treatments for chronic hepatitis C: An overview for paediatricians. World Journal of Gastroenterology 20:43, pages 15965.
Crossref